Following a particularly well received first phase of their clinical pilot program, medical technology company 4DMedical (ASX: 4DX) is advancing their respiratory imaging platform to Phase 2 of their clinical pilot program. Conducted with Australia’s leading medical imaging provider, I-MED Radiology Network, Phase 1 of the program saw radiologists use 4DMedical’s proprietary XV Lung Ventilation
Read More
Every year traditional methods of lung diagnostics worldwide cost US $31 billion dollars. The arguably outdated technologies include the x-ray (invented in 1895), spirometry (invented in 1846) and CT (invented in 1971). Each has their own pros and cons, yet there remains a strong need for low dose, minimally invasive, time efficient and cost effective
Read More
Invented in 1895 and becoming the standard in the early 1900s, the x-ray has long been the backbone of many medical diagnoses. The relatively unchanged technology has been commonplace for decades, but medtech company 4D Medical (ASX: 4DX) is rethinking the way we diagnose respiratory issues with their proprietary XV Technology™ and Permetium preclinical scanner.
Read More
Investors that missed out on the IPO for medtech company 4D Medical (ASX: 4DX) have had no qualms buying the stock on market with shares in 4DX opening at $1.47 when trading commenced this morning, more than double the IPO Offer Price of $0.73. The significant jump follows a similar trend among Australian investors that
Read More
While the number of companies set to list on the ASX is still quieter than usual, we are continuing to see many healthcare companies viewing COVID-19 as an opportunity to make their public debut. 4D Medical are a Melbourne-based medical technology company, who have spent the last 15 years developing lung imaging software. The ‘software
Read More